Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedJan 13, 2026
DataAggregated Company Financials
Companies5
  • 7D4.2%
  • 3M-1.5%
  • 1Y10.3%
  • YTD3.8%

In the last week, the Biotech industry is up 4.2%, with Genmab up 7.6%. In the same time, Zealand Pharma was down 8.2%. This takes the industry's 12 month performance to a gain of 10%. Looking forward, earnings are forecast to decline by 6.6% per year.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 13 Jan 2026DKK 178.2bDKK 40.7bDKK 19.0b6.4x9.4x4.4x
Thu, 11 Dec 2025DKK 174.1bDKK 40.7bDKK 19.0b6.1x9.1x4.3x
Sat, 08 Nov 2025DKK 159.1bDKK 39.1bDKK 16.9b10.4x9.4x4.1x
Mon, 06 Oct 2025DKK 184.1bDKK 38.8bDKK 16.7b12.7x11x4.7x
Wed, 03 Sep 2025DKK 151.9bDKK 39.0bDKK 16.8b11.6x9x3.9x
Fri, 01 Aug 2025DKK 131.9bDKK 27.5bDKK 7.5b12.9x17.6x4.8x
Sun, 29 Jun 2025DKK 120.1bDKK 26.9bDKK 7.3b10.5x16.4x4.5x
Tue, 27 May 2025DKK 130.5bDKK 28.0bDKK 7.9b10.4x16.5x4.7x
Thu, 24 Apr 2025DKK 124.6bDKK 27.3bDKK 7.7b11.3x16.2x4.6x
Sat, 22 Mar 2025DKK 139.8bDKK 27.3bDKK 7.7b11.9x18.2x5.1x
Mon, 17 Feb 2025DKK 162.8bDKK 27.7bDKK 7.8b12x20.8x5.9x
Wed, 15 Jan 2025DKK 165.1bDKK 26.0bDKK 4.7b17.4x35.2x6.3x
Fri, 13 Dec 2024DKK 167.8bDKK 26.0bDKK 4.7b17x35.7x6.4x
Sun, 10 Nov 2024DKK 178.0bDKK 26.0bDKK 4.3b22.2x41.4x6.8x
Tue, 08 Oct 2024DKK 176.0bDKK 25.5bDKK 5.5b21.4x32.2x6.9x
Thu, 05 Sep 2024DKK 200.0bDKK 25.5bDKK 5.5b25.1x36.5x7.8x
Sat, 03 Aug 2024DKK 199.2bDKK 24.8bDKK 5.6b18.4x35.4x8x
Mon, 01 Jul 2024DKK 188.2bDKK 24.8bDKK 5.6b17x33.4x7.6x
Wed, 29 May 2024DKK 177.6bDKK 24.8bDKK 5.6b18.4x31.5x7.2x
Fri, 26 Apr 2024DKK 173.3bDKK 23.9bDKK 5.0b18.1x34.4x7.2x
Sun, 24 Mar 2024DKK 193.4bDKK 23.9bDKK 5.0b19.8x38.5x8.1x
Tue, 20 Feb 2024DKK 176.6bDKK 22.8bDKK 4.2b24.3x41.9x7.8x
Thu, 18 Jan 2024DKK 170.6bDKK 23.3bDKK 4.2b23.7x41x7.3x
Sat, 16 Dec 2023DKK 172.6bDKK 23.3bDKK 4.2b25.6x41.5x7.4x
Mon, 13 Nov 2023DKK 168.3bDKK 22.7bDKK 4.3b21.3x39.2x7.4x
Wed, 11 Oct 2023DKK 193.6bDKK 22.0bDKK 4.7b22.5x40.9x8.8x
Fri, 08 Sep 2023DKK 198.7bDKK 22.0bDKK 4.7b23.1x42.1x9x
Sun, 06 Aug 2023DKK 190.2bDKK 20.6bDKK 3.9b36.7x49.1x9.2x
Tue, 04 Jul 2023DKK 198.8bDKK 19.5bDKK 4.4b40.5x45.1x10.2x
Thu, 01 Jun 2023DKK 208.4bDKK 19.5bDKK 4.4b40.9x47.3x10.7x
Sat, 29 Apr 2023DKK 209.6bDKK 17.9bDKK 4.1b32.8x51.2x11.7x
Mon, 27 Mar 2023DKK 194.8bDKK 17.9bDKK 3.5b30.5x55x10.9x
Wed, 22 Feb 2023DKK 210.7bDKK 14.7bDKK 3.3b32x64.4x14.3x
Fri, 20 Jan 2023DKK 206.4bDKK 14.7bDKK 3.3b31.3x63.1x14x
Price to Earnings Ratio

63.1x


Total Market Cap: DKK 206.4bTotal Earnings: DKK 3.3bTotal Revenue: DKK 14.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 33.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.4x which is lower than its 3-year average PE of 33.2x.
  • The 3-year average PS ratio of 7.4x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 80% per year over the last three years.
  • Revenues for these companies have grown 40% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market4.48%
Healthcare7.98%
Biotech4.22%
Biotech4.22%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 2.14k1.3%
+DKK 1.7b		36.1%PE13x
BAVA Bavarian NordicDKK 198.550.5%
+DKK 82.2m		2.7%PE6.4x

Latest News

ZEAL
DKK 410.40
Zealand Pharma
7D
-4.9%
1Y
-41.0%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
BAVA
DKK 198.55
Bavarian Nordic
7D
0.5%
1Y
2.7%

BAVA: HERA Procurement Contract And Mpox Demand Are Expected To Drive Upside

Analysts have kept their price target for Bavarian Nordic unchanged at €260. This reflects only small tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions rather than a shift in their overall view.
GMAB
DKK 2,143.00
Genmab
7D
1.3%
1Y
36.1%

GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing

Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).
BIOPOR
DKK 1.06
BioPorto
7D
-0.6%
1Y
-28.4%
STRAP
DKK 684.00
Strategic Partners
7D
-6.0%
1Y
-15.6%